Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Thrombosis and Thrombolysis

17.05.2024

Cancer progression and tumor hypercoagulability: a platelet perspective

verfasst von: Yifan Zhang, Jingtong Zeng, Shihao Bao, Bo Zhang, Xianjie Li, Hanqing Wang, Yuan Cheng, Hao Zhang, Lingling Zu, Xiaohong Xu, Song Xu, Zuoqing Song

Erschienen in: Journal of Thrombosis and Thrombolysis

Einloggen, um Zugang zu erhalten

Abstract

Venous thromboembolism, which is common in cancer patients and accompanies or even precedes malignant tumors, is known as cancer-related thrombosis and is an important cause of cancer- associated death. At present, the exact etiology of the elevated incidence of venous thrombosis in cancer patients remains elusive. Platelets play a crucial role in blood coagulation, which is intimately linked to the development of arterial thrombosis. Additionally, platelets contribute to tumor progression and facilitate immune evasion by tumors. Tumor cells can interact with the coagulation system through various mechanisms, such as producing hemostatic proteins, activating platelets, and directly adhering to normal cells. The relationship between platelets and malignant tumors is also significant. In this review article, we will explore these connections.
Literatur
1.
2.
Curigliano G, Lenihan D, Fradley M et al (2020) Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol: Off J Eur Soc Med Oncol 31(2):171–190CrossRef
3.
Tavares V, Neto BV, Vilas-Boas MI et al (2022) Impact of hereditary thrombophilia on cancer-associated thrombosis, tumour susceptibility and progression: a review of existing evidence. Biochim Biophys Acta 1877(5):188778
4.
5.
6.
Laporte S, Mismetti P, Décousus H et al (2008) Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 117(13):1711–1716PubMedCrossRef
7.
Farge D, Frere C, Connors JM et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566–e581PubMedCrossRef
8.
9.
Gran OV, Smith EN, Brækkan SK et al (2016) Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica 101(9):1046–1053PubMedPubMedCentralCrossRef
10.
Reitsma PH, Versteeg HH, Middeldorp S (2012) Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 32(3):563–568PubMedCrossRef
11.
Tavares V, Pinto R, Assis J et al (2020) Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: linkage to ovarian tumour behaviour. Biochim Biophys Acta 1873(1):188331
12.
Skille H, Paulsen B, Hveem K et al (2021) Prothrombotic genotypes and risk of venous thromboembolism in occult cancer. Thromb Res 205:17–23PubMedCrossRef
13.
Buijs JT, Versteeg HH (2020) Genes and proteins associated with the risk for cancer-associated thrombosis. Thromb Res 191:S43–S49PubMedCrossRef
14.
Moik F, Chan W-SE, Wiedemann S et al (2021) Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 137(12):1669–1678PubMedPubMedCentralCrossRef
15.
Sussman TA, Li H, Hobbs B et al (2021) Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J Immunother Cancer 9(1):e001719PubMedPubMedCentralCrossRef
16.
Roopkumar J, Swaidani S, Kim AS et al (2021) Increased incidence of venous thromboembolism with cancer immunotherapy. Med (New York, NY) 2(4):423–434
17.
Galmiche A, Rak J, Roumenina LT et al (2022) Coagulome and the tumor microenvironment: an actionable interplay. Trends Cancer 8(5):369–383PubMedCrossRef
18.
Falanga A, Schieppati F, Russo L (2019) Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients. Cancer Treat Res 179:11–36PubMedCrossRef
19.
20.
Posch F, Riedl J, Reitter E-M et al (2016) Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A multi-state model. Thromb Haemost 115(4):817–826PubMedCrossRef
21.
Riedl JM, Schwarzenbacher E, Moik F et al (2022) Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing first-line chemotherapy with FOLFIRINOX or gemcitabine/nab-paclitaxel. Thromb Haemost 122(4):633–645PubMedCrossRef
22.
Ay C, Pabinger I, Cohen AT (2017) Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 117(2):219–230PubMedCrossRef
23.
Gao S, Ma J-J, Lu C (2014) Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis. Tumour Biol 35(1):603–613PubMedCrossRef
24.
Ashrani AA, Gullerud RE, Petterson TM et al (2016) Risk factors for incident venous thromboembolism in active cancer patients: a population based case-control study. Thromb Res 139:29–37PubMedPubMedCentralCrossRef
25.
Cohen AT, Katholing A, Rietbrock S et al (2017) Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 117(1):57–65PubMedCrossRef
26.
Königsbrügge O, Pabinger I, Ay C (2014) Risk factors for venous thromboembolism in cancer: novel findings from the Vienna cancer and thrombosis study (CATS). Thromb Res 133(Suppl 2):S39–S43PubMedCrossRef
27.
Fiedler T, Rabe M, Mundkowski RG et al (2018) Adipose-derived mesenchymal stem cells release microvesicles with procoagulant activity. Int J Biochem Cell Biol 100:49–53PubMedCrossRef
28.
Farge D, Le Maignan C, Doucet L et al (2019) Women, thrombosis, and cancer. Thromb Res 181(Suppl 1):S47–S53PubMedCrossRef
29.
Würtz M, Grove EL, Corraini P et al (2020) Comorbidity and risk of venous thromboembolism after hospitalization for first-time myocardial infarction: a population-based cohort study. J Thromb Haemost 18(8):1974–1985PubMedCrossRef
30.
Chaturvedi S, Braunstein EM, Yuan X et al (2020) Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 135(4):239–251PubMedPubMedCentralCrossRef
31.
Karasu A, Engbers MJ, Cushman M et al (2016) Genetic risk factors for venous thrombosis in the elderly in a case-control study. J Thromb Haemost 14(9):1759–1764PubMedCrossRef
32.
Ghouse J, Tragante V, Ahlberg G et al (2023) Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism. Nat Genet 55(3):399–409PubMedCrossRef
33.
Raghunathan S, Rayes J, Sen Gupta A (2022) Platelet-inspired nanomedicine in hemostasis thrombosis and thromboinflammation. J Thromb Haemost 20(7):1535–1549PubMedPubMedCentralCrossRef
34.
Levi M (2019) Disseminated intravascular coagulation in cancer: an update. Semin Thromb Hemost 45(4):342–347PubMedCrossRef
35.
Mitrugno A, Tassi Yunga S, Sylman JL et al (2019) The role of coagulation and platelets in colon cancer-associated thrombosis. Am J Physiol Cell Physiol 316(2):C264–C273PubMedCrossRef
36.
Ghoshal K, Bhattacharyya M (2014) Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Sci World J 2014:781857CrossRef
37.
38.
Levin J, Conley CL (1964) Thrombocytosis associated with malignant disease. Arch Intern Med 114:497–500PubMedCrossRef
39.
40.
Zhang X, Ran Y (2015) Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis. Int J Clin Exp Med 8(4):5379–5387PubMedPubMedCentral
41.
Gu D, Szallasi A (2017) Thrombocytosis portends adverse prognosis in colorectal cancer: a meta-analysis of 5,619 patients in 16 individual studies. Anticancer Res 37(9):4717–4726PubMed
42.
Ji Y, Sheng L, Du X et al (2015) Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients. Platelets 26(2):138–142PubMedCrossRef
43.
Harano K, Kogawa T, Wu J et al (2017) Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Res Treat 166(3):819–832PubMedCrossRef
44.
Zarà M, Canobbio I, Visconte C et al (2018) Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells. Cell Signal 48:45–53PubMedCrossRef
45.
46.
Chang J, Jiang L, Wang Y et al (2015) 12/15 Lipoxygenase regulation of colorectal tumorigenesis is determined by the relative tumor levels of its metabolite 12-HETE and 13-HODE in animal models. Oncotarget 6(5):2879–2888PubMedCrossRef
47.
Heinmöller E, Weinel RJ, Heidtmann HH et al (1996) Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. J Cancer Res Clin Oncol 122(12):735–744PubMedCrossRef
48.
49.
Nilsson RJA, Karachaliou N, Berenguer J et al (2016) Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget 7(1):1066–1075PubMedCrossRef
50.
51.
Yao L, Dong H, Luo Y et al (2014) Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer. PLoS One 9(4):e96206PubMedPubMedCentralCrossRef
52.
Alkozai EM, Porte RJ, Adelmeijer J et al (2015) Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma. Platelets 26(6):577–582PubMedCrossRef
53.
Kim SJ, Choi IK, Park KH et al (2004) Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn J Clin Oncol 34(4):184–190PubMedCrossRef
54.
Peterson JE, Zurakowski D, Italiano JE et al (2012) VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 15(2):265–273PubMedCrossRef
55.
Duvernay MT, Temple KJ, Maeng JG et al (2017) Contributions of protease-activated receptors PAR1 and PAR4 to thrombin-induced GPIIbIIIa activation in human platelets. Mol Pharmacol 91(1):39–47PubMedPubMedCentralCrossRef
56.
Reitter EM, Kaider A, Ay C et al (2016) Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. J Thromb Haemost 14(2):294–305PubMedCrossRef
57.
58.
Gardiner C, Harrison P, Belting M et al (2015) Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational Day. J Extracell Vesicles 4:26901PubMedCrossRef
59.
Mackman N, Tilley RE, Key NS (2007) Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 27(8):1687–1693PubMedCrossRef
60.
Gregory SA, Morrissey JH, Edgington TS (1989) Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 9(6):2752–2755PubMedPubMedCentral
61.
Geddings JE, Mackman N (2013) Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 122(11):1873–1880PubMedPubMedCentralCrossRef
62.
Tang X, Zhang Z, Fang M et al (2020) Transferrin plays a central role in coagulation balance by interacting with clotting factors. Cell Res 30(2):119–132PubMedCrossRef
63.
György B, Szabó TG, Pásztói M et al (2011) Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci: CMLS 68(16):2667–2688PubMedCrossRef
64.
65.
Tesselaar MET, Romijn FPHTM, Van Der Linden IK et al (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5(3):520–527PubMedCrossRef
66.
Mulder FI, Horváth-Puhó E, van Es N et al (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137(14):1959–1969PubMedCrossRef
67.
Gomes T, Várady CBS, Lourenço AL et al (2019) IL-1β blockade attenuates thrombosis in a neutrophil extracellular trap-dependent breast cancer model. Front Immunol 10:2088PubMedPubMedCentralCrossRef
68.
Reusswig F, Fazel Modares N, Brechtenkamp M et al (2021) Efficiently restored thrombopoietin production by Ashwell-Morell receptor and IL-6R induced Janus Kinase 2/Signal transducer and activator of transcription signaling early after partial hepatectomy. Hepatology 74(1):411–427PubMedCrossRef
69.
Zucchella M, Dezza L, Pacchiarini L et al (1989) Human tumor cells cultured “in vitro” activate platelet function by producing ADP or thrombin. Haematologica 74(6):541–545PubMed
70.
71.
van Es N, Le Gal G, Otten H-M et al (2017) Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data. Ann Intern Med 167(6):410–417PubMedCrossRef
72.
73.
Pihusch R, Danzl G, Scholz M et al (2002) Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 94(12):3120–3126PubMedCrossRef
74.
Tinholt M, Viken MK, Dahm AE et al (2014) Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. BMC Cancer 14:845PubMedPubMedCentralCrossRef
75.
Maragoudakis ME, Tsopanoglou NE, Andriopoulou P et al (2000) Effects of thrombin/thrombosis in angiogenesis and tumour progression. Matrix Biol: J Int Soc Matrix Biol 19(4):345–351CrossRef
76.
Green D (2010) Karpatkin S Role of thrombin as a tumor growth factor. Cell Cycle (Georgetown, Tex). 9(4):656–661PubMedCrossRef
77.
Eroğlu A, Oztürk A, Akar N (2011) Association between the -402GA, -401GT, and -323ins10-bp polymorphisms of factor VII gene and breast cancer. Breast Cancer (Tokyo, Japan) 18(4):282–285PubMedCrossRef
78.
Fang J, Yuan Q, Du Z et al (2021) Contribution of factor VII polymorphisms to coagulopathy in patients with isolated traumatic brain injury. Clin Neurol Neurosurg 208:106836PubMedCrossRef
79.
Ken-Dror G, Drenos F, Humphries SE et al (2010) Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men. J Thromb Haemost 8(11):2394–2403PubMedPubMedCentralCrossRef
80.
DuPre SA, Hunter KW (2007) Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol 82(1):12–24PubMedCrossRef
81.
Kowanetz M, Wu X, Lee J et al (2010) Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A 107(50):21248-21255
82.
Demers M, Krause DS, Schatzberg D et al (2012) Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A 109(32):13076-13081
83.
Jensvoll H, Blix K, Brækkan SK et al (2014) Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study. PLoS One 9(3):e92011PubMedPubMedCentralCrossRef
84.
Khorana AA, Francis CW, Culakova E et al (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104(12):2822–2829PubMedCrossRef
85.
Simanek R, Vormittag R, Ay C et al (2010) High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 8(1):114–120PubMedCrossRef
86.
Thaler J, Ay C, Kaider A et al (2014) Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro-oncology 16(12):1645–1651PubMedPubMedCentralCrossRef
87.
Riedl J, Preusser M, Nazari PMS et al (2017) Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood 129(13):1831–1839PubMedCrossRef
88.
Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907PubMedPubMedCentralCrossRef
89.
Granger JM, Kontoyiannis DP (2009) Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer 115(17):3919–3923PubMedCrossRef
90.
Kasuga I, Makino S, Kiyokawa H et al (2001) Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 92(9):2399–2405PubMedCrossRef
91.
Ruka W, Rutkowski P, Kaminska J et al (2001) Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol: Off J Eur Soc Med Oncol 12(10):1423–1432CrossRef
92.
Blix K, Jensvoll H, Brækkan SK et al (2013) White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism–the Tromsø study. PLoS One 8(9):e73447PubMedPubMedCentralCrossRef
93.
Pabinger I, Posch F (2014) Flamethrowers: blood cells and cancer thrombosis risk. Hematol Am Soc Hematol Educ Program 2014(1):410–417CrossRef
94.
Khorana AA, Francis CW, Menzies KE et al (2008) Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 6(11):1983–1985PubMedPubMedCentralCrossRef
95.
Thaler J, Ay C, Mackman N et al (2012) Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 10(7):1363–1370PubMedCrossRef
96.
Bharthuar A, Khorana AA, Hutson A et al (2013) Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 132(2):180–184PubMedCrossRef
97.
Verheul HM, Hoekman K, Lupu F et al (2000) Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res: Off J Am Assoc Cancer Res 6(1):166–171
98.
Gordon SG, Mielicki WP (1997) Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis: Int J Haemost Thromb 8(2):73–86CrossRef
99.
Tinholt M, Vollan HKM, Sahlberg KK et al (2015) Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. Breast Cancer Res: BCR 17(1):44PubMedPubMedCentralCrossRef
100.
Bazzarelli AK, Scheer AS, Tai LH et al (2016) Tissue factor pathway inhibitor gene polymorphism -33T → C predicts improved disease-free survival in colorectal cancer. Ann Surg Oncol 23(7):2274–2280PubMedCrossRef
101.
102.
Ruf W (2007) Tissue factor and PAR signaling in tumor progression. Thromb Res 120(Suppl 2):S7-12PubMedCrossRef
103.
Tumors DHF (2019) Wounds that do not heal—a historical perspective with a focus on the fundamental roles of increased vascular permeability and clotting. Semin Thromb Hemost 45(06):576–592CrossRef
104.
105.
Lundbech M, Krag AE, Christensen TD et al (2020) Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients. Thromb Res 186:80–85PubMedCrossRef
106.
Orcutt SJ, Pietropaolo C, Krishnaswamy S (2002) Extended interactions with prothrombinase enforce affinity and specificity for its macromolecular substrate. J Biol Chem 277(48):46191–46196PubMedCrossRef
107.
108.
Ronchetti L, Terrenato I, Ferretti M et al (2023) Correction: circulating cell free DNA and citrullinated histone H3 as useful biomarkers of NETosis in endometrial cancer. J Exp Clin Cancer Res 42(1):278PubMedPubMedCentralCrossRef
109.
110.
111.
Kansas GS (1996) Selectins and their ligands: current concepts and controversies. Blood 88(9):3259–3287PubMedCrossRef
112.
Vandendries ER, Furie BC, Furie B (2004) Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 92(3):459–466PubMedCrossRef
113.
Michelson AD, Barnard MR, Hechtman HB et al (1996) In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 93(21):11877-11882
114.
Palabrica T, Lobb R, Furie BC et al (1992) Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359(6398):848–851PubMedCrossRef
115.
Frenette PS, Johnson RC, Hynes RO et al (1995) Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A 92(16):7450-7454
116.
Chong BH, Murray B, Berndt MC et al (1994) Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 83(6):1535–1541PubMedCrossRef
117.
118.
Tawil N, Bassawon R, Meehan B et al (2021) Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv 5(6):1682–1694PubMedPubMedCentralCrossRef
119.
Suzuki-Inoue K, Kato Y, Inoue O et al (2007) Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 282(36):25993–26001PubMedCrossRef
120.
Mege D, Aubert M, Lacroix R et al (2019) Involvement of platelets in cancers. Semin Thromb Hemost 45(6):569–575PubMedCrossRef
121.
Cedervall J, Hamidi A, Olsson A-K (2018) Platelets, NETs and cancer. Thromb Res 164(Suppl 1):S148–S152PubMedCrossRef
122.
Connolly GC, Phipps RP, Francis CW (2014) Platelets and cancer-associated thrombosis. Semin Oncol 41(3):302–310PubMedCrossRef
123.
Riedl J, Pabinger I, Ay C (2014) Platelets in cancer and thrombosis. Hamostaseologie 34(1):54–62PubMedCrossRef
124.
Larocca A, Cavallo F, Bringhen S et al (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4):933–939PubMedCrossRef
125.
Shai A, Rennert HS, Rennert G et al (2014) Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. Gynecol Oncol 133(2):304–308PubMedCrossRef
126.
127.
Riedl J, Hell L, Kaider A et al (2016) Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets 27(1):80–85PubMedCrossRef
128.
Poruk KE, Firpo MA, Huerter LM et al (2010) Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev: Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 19(10):2605–2610CrossRef
129.
Mezouar S, Darbousset R, Dignat-George F et al (2015) Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer 136(2):462–475PubMedCrossRef
130.
Geddings JE, Hisada Y, Boulaftali Y et al (2016) Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost 14(1):153–166PubMedCrossRef
131.
Medina C, Harmon S, Inkielewicz I et al (2012) Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin. Br J Pharmacol 166(3):938–949PubMedPubMedCentralCrossRef
132.
Bastida E, Ordinas A, Jamieson GA (1981) Differing platelet aggregating effects by two tumor cell lines: absence of role for platelet-derived ADP. Am J Hematol 11(4):367–378PubMedCrossRef
133.
Boukerche H, Berthier-Vergnes O, Penin F et al (1994) Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets. Br J Haematol 87(4):763–772PubMedCrossRef
134.
Bastida E, Escolar G, Almirall L et al (1986) Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. Thromb Haemost 55(3):333–337PubMedCrossRef
135.
Camez A, Dupuy E, Bellucci S et al (1986) Human platelet-tumor cell interactions vary with the tumor cell lines. Invasion Metastasis 6(6):321–334PubMed
136.
Alonso-Escolano D, Strongin AY, Chung AW et al (2004) Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol 141(2):241–252PubMedCrossRef
137.
Jurasz P, Sawicki G, Duszyk M et al (2001) Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Can Res 61(1):376–382
138.
Palacios-Acedo AL, Mezouar S, Mège D et al (2021) P2RY12-inhibitors reduce cancer-associated thrombosis and tumor growth in pancreatic cancers. Front Oncol 11:704945PubMedPubMedCentralCrossRef
139.
140.
Ishikawa S, Miyashita T, Inokuchi M et al (2016) Platelets surrounding primary tumor cells are related to chemoresistance. Oncol Rep 36(2):787–794PubMedCrossRef
141.
142.
Rolfes V, Idel C, Pries R et al (2018) PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget 9(44):27460–27470PubMedPubMedCentralCrossRef
143.
Zamora C, Cantó E, Nieto JC et al (2017) Binding of platelets to lymphocytes: a potential anti-inflammatory therapy in rheumatoid arthritis. J Immunol (Baltimore, Md: 1950) 198(8):3099–3108CrossRef
144.
145.
146.
Lisman T (2018) Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease. Cell Tissue Res 371(3):567–576PubMedCrossRef
147.
Coffelt SB, Kersten K, Doornebal CW et al (2015) IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522(7556):345–348PubMedPubMedCentralCrossRef
148.
de Kleijn S, Langereis JD, Leentjens J et al (2013) IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLoS One 8(8):e72249PubMedPubMedCentralCrossRef
149.
150.
Corvigno S, Johnson AM, Wong K-K et al (2022) Novel markers for liquid biopsies in cancer management: circulating platelets and extracellular vesicles. Mol Cancer Ther 21(7):1067–1075PubMedPubMedCentralCrossRef
151.
Strauss J, Heery CR, Schlom J et al (2018) Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors. Clin Cancer Res: Off J Am Assoc Cancer Res 24(6):1287–1295CrossRef
152.
Goshua G, Sinha P, Hendrickson JE et al (2021) Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 137(7):969–976PubMedPubMedCentralCrossRef
153.
Loschi M, Porcher R, Barraco F et al (2016) Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol 91(4):366–370PubMedCrossRef
154.
Cofiell R, Kukreja A, Bedard K et al (2015) Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 125(21):3253–3262PubMedPubMedCentralCrossRef
155.
156.
Scully M, Knöbl P, Kentouche K et al (2017) Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood 130(19):2055–2063PubMedPubMedCentralCrossRef
157.
158.
Huang J, Li X, Shi X et al (2019) Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol 12(1):26PubMedPubMedCentralCrossRef
159.
Giordano A, Musumeci G, D’Angelillo A et al (2016) Effects of glycoprotein IIb/IIIa antagonists: anti platelet aggregation and beyond. Curr Drug Metab 17(2):194–203PubMedCrossRef
160.
Ulrichts H, Silence K, Schoolmeester A et al (2011) Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 118(3):757–765PubMedCrossRef
161.
Callewaert F, Roodt J, Ulrichts H et al (2012) Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 120(17):3603–3610PubMedCrossRef
162.
Scully M, Cataland SR, Peyvandi F et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380(4):335–346PubMedCrossRef
163.
Völker LA, Kaufeld J, Balduin G et al (2023) Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. J Thromb Haemost 21(3):559–572PubMedCrossRef
164.
Peyvandi F, Scully M, Kremer Hovinga JA et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374(6):511–522PubMedCrossRef
165.
Whilding LM, Halim L, Draper B et al (2019) CAR T-cells targeting the integrin αvβ6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel) 11(5):674. https://​doi.​org/​10.​3390/​cancers11050674
166.
Haider T, Sandha KK, Soni V et al (2020) Recent advances in tumor microenvironment associated therapeutic strategies and evaluation models. Mater Sci Eng C Mater Biol Appl 116:111229PubMedCrossRef
167.
168.
Liu Y, Castro Bravo KM, Liu J (2021) Targeted liposomal drug delivery: a nanoscience and biophysical perspective. Nanoscale Horiz 6(2):78–94PubMedCrossRef
169.
Shao J, Zaro J, Shen Y (2020) Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate. Int J Nanomedicine 15:9355–9371PubMedPubMedCentralCrossRef
170.
171.
Abe K, Yoshimura H, Tanaka H et al (2004) Comparison of conventional and diffusion-weighted MRI and proton MR spectroscopy in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like events. Neuroradiology 46(2):113–117PubMedCrossRef
172.
Crescente M, Mezzasoma AM, Del Pinto M et al (2011) Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin. Platelets 22(3):179–187PubMedCrossRef
173.
Paniccia R, Antonucci E, Gori AM et al (2007) Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 5(9):1839–1847PubMedCrossRef
174.
Lele M, Sajid M, Wajih N et al (2001) Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 104(5):582–587PubMedCrossRef
175.
176.
Mori J, Pearce AC, Spalton JC et al (2008) G6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2. J Biol Chem 283(51):35419–35427PubMedPubMedCentralCrossRef
177.
Perrault C, Mangin P, Santer M et al (2003) Role of the intracellular domains of GPIb in controlling the adhesive properties of the platelet GPIb/V/IX complex. Blood 101(9):3477–3484PubMedCrossRef
178.
Saidak Z, Soudet S, Lottin M et al (2021) A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment. Cancer Immunol Immunother: CII 70(4):923–933PubMedCrossRef
179.
Posch F, Riedl J, Reitter E-M et al (2020) Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: a prospective study. J Thromb Haemost 18(6):1348–1356PubMedPubMedCentralCrossRef
180.
Marchetti M, Giaccherini C, Masci G et al (2020) Thrombin generation predicts early recurrence in breast cancer patients. J Thromb Haemost 18(9):2220–2231PubMedCrossRef
181.
Pantel K, Alix-Panabières C (2019) Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol 16(7):409–424PubMedCrossRef
182.
Keller L, Pantel K (2019) Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer 19(10):553–567PubMedCrossRef
Metadaten
Titel
Cancer progression and tumor hypercoagulability: a platelet perspective
verfasst von
Yifan Zhang
Jingtong Zeng
Shihao Bao
Bo Zhang
Xianjie Li
Hanqing Wang
Yuan Cheng
Hao Zhang
Lingling Zu
Xiaohong Xu
Song Xu
Zuoqing Song
Publikationsdatum
17.05.2024
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-024-02993-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise